# OnCo record loxo-oncology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/loxo-oncology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "loxo-oncology" ;
  schema:name "Loxo Oncology"@en ;
  schema:alternateName "Loxo Oncology, Inc."@en, "NASDAQ:LOXO"@en ;
  schema:description "Loxo Oncology developed pills aimed at single gene changes that drive some cancers, including selpercatinib for RET-altered cancers and pirtobrutinib for some blood cancers. Eli Lilly bought the company in 2019."@en ;
  schema:url <https://onco.cc/companies/loxo-oncology/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1581720/000119312519003083/d674169dex991.htm>, <https://www.sec.gov/Archives/edgar/data/1581720/000119312519042505/d664418d8k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/mantle-cell-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ret/>, <https://onco.cc/targets/btk/>, <https://onco.cc/targets/ntrk/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pirtobrutinib/>, <https://onco.cc/drugs/larotrectinib/> .